Mutational landscape of sGBM guides MET-targeted trial in brain tumor

2018-10-18 13:58:47|publisher: admin| Views: 222

Recently, Dr. Jiang and his group uncovered the mutational landscape of secondary glioblastoma (sGBM) in East Asian cohort, through a fruitful collaboration mainly with Dr. Jiguang Wang's team from Hong Kong University of Science and Technoloy (HKUST). This systematic study reveals genomic differences among low-grade glioma, primary glioblastoma and sGBM. Strikingly, we discovered that genomic mutations that lead to METex14 are highly enriched in sGBM cases, and the presence of METex14 transcripts is an important biomarker that predicts significantly worse patient survival. More importantly, MET protein is an actionable drug target, which has been verified in a MET-targeted Phase I clinical trial led by our collaborator at Beijing Tiantan Hospital. Out of the six sGBM patients who completed the trial, two achieved partial response, two achieved stable disease, and two have progressed disease. This encouraging result highlights the great potential of precision cancer medicine in treating previous incurable cancers by tailoring particular therapies according to personalised genomic information.